Recent News

• 11.25.2025 - CytomX Therapeutics to Present at Upcoming December Investor Conferences
• 11.13.2025 - CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
• 11.06.2025 - CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
• 11.04.2025 - CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
• 10.30.2025 - CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
• 10.20.2025 - CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.06.2025 - 144 Report of proposed sale of securities
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 8-K Current report
• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors